Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis opts to buy Selexys Pharma

by Rick Mullin
November 28, 2016 | A version of this story appeared in Volume 94, Issue 47

Novartis has acquired Selexys Pharmaceuticals, a specialist in hematological and inflammatory disease. The deal comes after successful Phase II clinical trials of Selexys’ SelG1, an antibody that treats vaso-occlusive pain in patients with sickle cell disease. The value of the deal could amount to $665 million, including an undisclosed up-front payment and milestone payments. Novartis obtained the exclusive right to acquire Selexys and SelG1 in 2012.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.